InvestorsHub Logo
Followers 99
Posts 2761
Boards Moderated 2
Alias Born 02/10/2004

Re: TheMonolith post# 4813

Saturday, 04/07/2018 10:56:04 PM

Saturday, April 07, 2018 10:56:04 PM

Post# of 6315
Agreed, NMUS trades at a fraction of the value of CBIS, IN.to, MJNA, and LXRP....all of which are also pre-clinical, pre-revenue companies with debatable drug candidates and credibility in pharmaceutical development experience. I don't see any good reason why Nemus trades at less than half the average valuation of the aforementioned companies. On a relative valuation basis, I think it deserves to be valued above the average of those other companies valuations....being affiliated with the only US approved research agency has to be worth something more.

I also agree there should be more news coming on the pipeline update, capital restructuring, and plan to uplist.

"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SKYE News